ATC Group: J01FA Macrolides

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J01FA in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J01 Antibacterials for systemic use
3 J01F Macrolides, lincosamides and streptogramins
4 J01FA Macrolides

Group J01FA contents

Code Title
J01FA01 Erythromycin
J01FA02 Spiramycin
J01FA03 Midecamycin
J01FA05 Oleandomycin
J01FA06 Roxithromycin
J01FA07 Josamycin
J01FA08 Troleandomycin
J01FA09 Clarithromycin
J01FA10 Azithromycin
J01FA11 Miocamycin
J01FA12 Rokitamycin
J01FA13 Dirithromycin
J01FA14 Flurithromycin
J01FA15 Telithromycin

Active ingredients in J01FA

Active Ingredient

Azithromycin is a macrolide antibiotic belonging to the azalide group. The molecule is constructed by adding a nitrogen atom to the lactone ring of erythromycin A. The mechanism of action of azithromycin is based upon the suppression of bacterial protein synthesis by means of binding to the ribosomal 50S sub-unit and inhibition of peptide translocation.

Clarithromycin is a semi-synthetic derivative of erythromycin A. It exerts its antibacterial action by selectively binding to the 50s ribosomal sub-unit of susceptible bacteria preventing translocation of activated amino acids. It inhibits the intracellular protein synthesis of susceptible bacteria.

Erythromycin exerts its antimicrobial action by binding to the 50S ribosomal sub-unit of susceptible microorganisms and suppresses protein synthesis. Erythromycin is bacteriostatic and bactericidal depending on its concentration and the type of organism.

Roxithromycin is a semi-synthetic macrolide antibiotic. Roxithromycin is bacteriostatic at low concentrations and bactericidal at high concentrations. It binds to the 50S subunit of the 70S ribosome, thereby disrupting bacterial protein synthesis.

Antibacterial antibiotic belonging to the macrolides family. Spiramycin inhibits translocation by binding to bacterial 50S ribosomal subunits with an apparent 1:1 stoichiometry. This antibiotic is a potent inhibitor of the binding to the ribosome of both donor and acceptor substrates. Spiramycin induces rapid breakdown of polyribosomes, an effect which has formerly been interpreted as occurring by normal ribosomal run-off followed by an antibiotic-induced block at or shortly after initiation of a new peptide.

Telithromycin is a semisynthetic derivative of erythromycin A belonging to the ketolides, a class of antibacterial agents related to macrolides.

Related product monographs

Document Type Information Source  
 AZIMAX Tablet MPI, US: SPL/PLR Web Search
 CLAREM Film-coated tablet MPI, EU: SmPC Υπουργείο Υγείας (CY)
 CLERON Film-coated tablet MPI, EU: SmPC Υπουργείο Υγείας (CY)
 ERMYCIN Film-coated tablet MPI, EU: SmPC Υπουργείο Υγείας (CY)
 ERY-TAB Delayed-release tablet MPI, US: SPL/Old FDA, National Drug Code (US)
 ERYTHROCIN Film coated tablets MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 ERYTHROPED SF Granules MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 KLACID Film-coated tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)
 Klaricid 250mg Tablets MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 KLERIMED Film coated tablet MPI, EU: SmPC Υπουργείο Υγείας (CY)
 PORPHYROCIN Film-coated tablet MPI, EU: SmPC Υπουργείο Υγείας (CY)
 ROVAMYCIN Film-coated tablet MPI, EU: SmPC
 ZEDBAC Powder for solution for infusion MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 ZITHROMAX Capsule, hard MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 ZITHROMAX Film-coated tablet / Powder for suspension MPI, US: SPL/PLR FDA, National Drug Code (US)
 ZITHROMAX Powder for solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)